Moderna, Inc. (MRNA) Factsheet
Moderna, Inc. (MRNA) Stock Analysis
Analysis from 10-Q filed 2025-11-06. Data as of Q4 2025.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC -32.3%. FCF margin -106.2%. D/E 0.1x. Source: 10-Q filed 2025-11-06.
| Metric | Value | Context |
|---|---|---|
| ROIC | -32.3% | Below expectations |
| FCF Margin | -106.2% | Cash flow pressure |
| Debt/Equity | 0.1x | Conservative leverage |
ROIC -32.3% — Bottom 50% of sector peers. FCF margin -106.2% — Bottom 10%.
Explore Moderna, Inc.: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for MRNA: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Moderna, Inc. earns -32.3% ROIC, Bottom 50% in Healthcare
ROIC TTM -32.3%, sector median -2.5%, Bottom 50%. DuPont: NOPAT margin -161.2% × asset turnover 0.2x. Gross margin 55.3%. Operating margin -158.1%. Source: 10-Q filed 2025-11-06.
| Metric | MRNA | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | -32.3% | Red flag | Below sector median of -2.5% |
| Return on Equity (ROE) | -29.3% | Red flag | Moderate equity returns |
| Gross Margin | 55.3% | Excellent | Strong pricing power |
| Operating Margin | -158.1% | Warning | Moderate operational efficiency |
Cash Flow: Moderna, Inc. generates $-2.1B FCF at -106.2% margin, positive NaN/8 quarters
FCF TTM $-2.1B. FCF margin -106.2%. OCF/Net income 0.7x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-06.
| Metric | MRNA | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | -106.2% | Red flag | Thin cash margins |
| Free Cash Flow (TTM) | $-2.1B | Red flag | Cash burn |
| OCF/Net Income | 0.7x | Adequate | Potential accrual concerns |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Moderna, Inc. at 0.1x leverage
Debt/Equity 0.1x. Net cash $5.2B. Source: 10-Q filed 2025-11-06.
| Metric | MRNA | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.1x | Excellent | Conservative capital structure |
| Net Cash Position | $5.2B | Excellent | Net cash positive |
Valuation: Moderna, Inc. trades at -4.1x earnings
P/E -4.1x. EV/Sales 3.1x. FCF yield -18.0%. Source: 10-Q filed 2025-11-06.
| Metric | MRNA | Rating | Context |
|---|---|---|---|
| P/E Ratio | -4.1x | Red flag | Reasonable valuation |
| EV/Sales | 3.1x | Good | Growth premium priced in |
| FCF Yield | -18.0% | Warning | Lower cash yield |
Capital Allocation: Moderna, Inc. returns 0.0% shareholder yield
Total shareholder yield 0.0%. Capital returned $0 TTM. Source: 10-Q filed 2025-11-06.
| Metric | MRNA | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 0.0% | Warning | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $0 | Adequate | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | -32.3% | Bottom 50% | - |
| Free Cash Flow Margin | -106.2% | Bottom 10% | - |
| Gross Margin | 55.3% | Bottom 50% | 0.9x below |
| Operating Margin | -158.1% | Top 5% | -68.7x below |
| Return on Equity (ROE) | -29.3% | Bottom 50% | - |
Financial Scorecard
| Metric | MRNA | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | -32.3% | Red flag | Bottom 50% of sector (median: -2.5%) |
| Free Cash Flow Margin | -106.2% | Red flag | Thin cash margins |
| Gross Margin | 55.3% | Excellent | Bottom 50% of sector (median: 64.7%) |
| Debt to Equity Ratio | 6.8% | Excellent | Conservative capital structure |
| Free Cash Flow Yield | -18.0% | Red flag | Growth-focused valuation |
Frequently Asked Questions
Q: What is Moderna, Inc.'s Return on Invested Capital (ROIC)?
Moderna, Inc. (MRNA) has a trailing twelve-month Return on Invested Capital (ROIC) of -32.3%. Sector median -2.5%. Source: 10-Q filed 2025-11-06.
Q: What is Moderna, Inc.'s Free Cash Flow Margin?
Moderna, Inc. (MRNA) has a free cash flow margin of -106.2%, generating $-2.1 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-06.
Q: What is Moderna, Inc.'s P/E ratio and how does it compare to peers?
Moderna, Inc. (MRNA) trades at a P/E ratio of -4.1x, which is above the sector median of N/A. EV/Sales 3.1x. Source: 10-Q filed 2025-11-06.
Q: What is Moderna, Inc.'s revenue and earnings growth?
Moderna, Inc. (MRNA) declined revenue by 39.9% year-over-year. EPS +21.7% YoY. Source: 10-Q filed 2025-11-06.
Q: How does Moderna, Inc. compare to competitors in Healthcare?
Compared to other companies in Healthcare, Moderna, Inc. (MRNA) shows: ROIC -32.3%, sector median -2.5% (Bottom 50%). FCF margin -106.2%, sector median 0.0%. Gross margin 55.3%, 9.4pp below sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Moderna, Inc.?
Quantitative warning flags for Moderna, Inc. (MRNA): 1) FCF margin -106.2% (below 5%); 2) ROIC declining -3.1% over 8 quarters. Source: 10-Q filed 2025-11-06.
Data Source: Data sourced from 10-Q filed 2025-11-06. TTM metrics as of Q4 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.